Company Page

Johns Hopkins University

Johns Hopkins University is a leading institution in the field of psychedelic research. The university's research group was the first in the United States to obtain regulatory approval to reinitiate research with psychedelics in healthy, psychedelic-naive volunteers in 2000. Since then, the university has published more than 60 peer-reviewed articles in respected scientific journals, making it the leading psychedelic research institution in the U.S. and one of the few leading groups worldwide. The research has demonstrated therapeutic effects in people suffering from a range of challenging conditions including addiction, existential distress caused by life-threatening disease, and treatment-resistant depression. It also has provided unique insight into neurophysiological mechanisms of action and the understanding of consciousness.

The Center for Psychedelic and Consciousness Research at Johns Hopkins University will focus on how psychedelics affect behavior, mood, cognition, brain function, and biological markers of health. Upcoming studies will determine the effectiveness of psilocybin as a new therapy for opioid addiction, Alzheimer's disease, post-traumatic stress disorder, post-treatment Lyme disease syndrome, anorexia nervosa and alcohol use in people with major depression. The researchers hope to create precision medicine treatments tailored to the specific needs of individual patients. The center is led by Paul B. Rothman, M.D., Dean of the Johns Hopkins University School of Medicine and CEO of Johns Hopkins Medicine, who stated that "Johns Hopkins is deeply committed to exploring innovative treatments for our patients. Our scientists have shown that psychedelics have real potential as medicine, and this new center will help us explore that potential."